Targeting Covid-19 with a Therapeutic Interfering Particle

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Raul  Andino
Organization: ALEPH THERAPEUTICS, INC.
Fiscal Year: 2021
Award: $300,000
Funding agency: National Institute of Allergy and Infectious Diseases

SUMMARY
 The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently
the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical
to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1,
a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA-funded program and shows potent
broad-spectrum activity across enteroviruses (Poliovirus Type 1 and 3, EVA71, and Coxsackievirus B3) as well
as respiratory viruses EV-D68/HRV-87, Rhinovirus A16 and A1B, and Influenza A. Recently we have shown
that eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice. Given
these results, it is critical to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. This work
could be the starting point for a potential therapy or prophylactic agent against SARS-CoV-2. This would also
represent a significant breakthrough for the development of a broad-spectrum antiviral agent that could
potentially target current and future viral threats.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><A549><ACE2><Acute><Alpha Particle Radiation><Alpha Particles><Alpha Radiation><Animal Experiments><Animal Model><Animal Models and Related Studies><Antiviral Agents><Antiviral Drugs><Antivirals><Body Weight><Brunhilde Virus><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture Techniques><Cells><Clinical><Clinical Markers><CoV-2><CoV2><Coronaviridae><Coronavirus><Coxsackie Viruses><Coxsackievirus><Data><Development><Disease><Disorder><Drug or chemical Tissue Distribution><Enterovirus><Epithelial Cells><Funding><Future><Goals><Immune response><Immunological response><Infection><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><Innate Immune Response><K-18><K-18 conjugate><K18><K18 combination><Lung><Lung Respiratory System><Lung diseases><Measures><Messenger RNA><Mice><Mice Mammals><Monitor><Murine><Mus><Non-Polyadenylated RNA><Organoids><Orthomyxovirus Type A><Poliovirus Type 1><Process><Production><Public Health><Pulmonary Diseases><Pulmonary Disorder><RNA><RNA Gene Products><Respiratory Disease><Respiratory Epithelium><Respiratory System Disease><Respiratory System Disorder><Rhinovirus><Ribonucleic Acid><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Structure of respiratory epithelium><Therapeutic><Tissue Distribution><Toxic effect><Toxicities><Transgenic Mice><Type A Influenza><Viral><Virus><Work><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><base><cell culture><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><developmental><disease of the lung><disorder of the lung><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><evaluate efficacy><examine efficacy><experiment><experimental research><experimental study><hCoV19><host response><immune system response><immunoresponse><lipid nanoparticle><lung disorder><mRNA><model of animal><model organism><mouse model><murine model><nCoV2><new approaches><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel approaches><novel drug treatments><novel drugs><novel strategies><novel strategy><novel therapeutics><novel therapy><particle><prevent><preventing><programs><prophylactic><pulmonary><respiratory><respiratory virus><response to treatment><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><therapeutic response><treatment response><α Particles>